Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
2022-06-29
عنوان الدراسة
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.
داعم الدراسة
Celgene
دواء الدراسة
Ozanimod HCl
رقم بروتوكول الدراسة
RPC01-3201
حالة الدراسة
Ongoing
موقع الدراسة
KAUH-J
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。